A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer

ConclusionThe combination of metronomic CM with bevacizumab significantly improved PFS over CM alone, although there was no significant difference in OS. Oral metronomic chemotherapy alone has limited activity in advanced breast cancer.ClinicalTrials.gov Identifier: NCT00083031.Date of Registration: May 17, 2004.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research